Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology

ABSTRACT: This study uses proteome microarray technology/data to identify predictive biomarkers of neutralizing antibody response and potential new correlates of protective immunity in rubella virus serology.

ORGANISM(S): Homo sapiens Rubella virus vaccine strain RA27/3

PROVIDER: GSE104148 | GEO | 2017/09/23

SECONDARY ACCESSION(S): PRJNA411822

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Project description:Introduction//backgroundThe lack of standardization of the currently used commercial anti-rubella IgG antibody assays leads to frequent misinterpretation of results for samples with low/equivocal antibody concentration. The use of alternative approaches in rubella serology could add new information leading to a fuller understanding of rubella protective immunity and neutralizing antibody response after vaccination.MethodsWe applied microarray technology to measure antibodies to all rubella virus proteins in 75 high and 75 low rubella virus-specific antibody responders after two MMR vaccine doses. These data were used in multivariate penalized logistic regression modeling of rubella-specific neutralizing antibody response after vaccination.ResultsWe measured antibodies to all rubella virus structural proteins (i.e., the glycoproteins E1 and E2 and the capsid C protein) and to the non-structural protein P150. Antibody levels to each of these proteins were: correlated with the neutralizing antibody titer (p<0.006); demonstrated differences between the high and the low antibody responder groups (p<0.008); and were components of the model associated with/predictive of vaccine-induced rubella virus-specific neutralizing antibody titers (misclassification error = 0.2).ConclusionOur study supports the use of this new technology, as well as the use of antibody profiles/patterns (rather than single antibody measures) as biomarkers of neutralizing antibody response and correlates of protective immunity in rubella virus serology.

| S-EPMC5690594 | biostudies-literature

Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology

Project description:Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology

| PRJNA411822 | ENA

Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.

Project description:IntroductionComprehensive evaluation of measles-specific humoral immunity after vaccination is important for determining new and/or additional correlates of vaccine immunogenicity and efficacy.MethodsWe used a novel proteome microarray technology and statistical modeling to identify factors and models associated with measles-specific functional protective immunity in 150 measles vaccine recipients representing the extremes of neutralizing antibody response after two vaccine doses.ResultsOur findings demonstrate a high seroprevalence of antibodies directed to the measles virus (MV) phosphoprotein (P), nucleoprotein (N), as well as antibodies to the large polymerase (L) protein (fragment 1234 to 1900 AA). Antibodies to these proteins, in addition to anti-F antibodies (and, to a lesser extent, anti-H antibodies), were correlated with neutralizing antibody titer and/or were associated with and predictive of neutralizing antibody response.ConclusionOur results identify antibodies to specific measles virus proteins and statistical models for monitoring and assessment of measles-specific functional protective immunity in vaccinated individuals.

| S-EPMC4379563 | biostudies-literature

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer ImmunotherapyRepurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

Project description:In this study, we show that intratumoral injections of the trivalent measles, mumps, and rubella (MMR) live attenuated viral vaccine (LAVs) modulate a potent cytotoxic T cells immune response, resulting in tumor growth inhibition and improved survival in syngeneic mouse models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC).

2022-10-27 | PXD031295 | Pride

Vaccine measles, mumps, rubella, chickenpox

Project description:Vaccine measles, mumps, rubella, chickenpox Metagenome

| PRJNA493815 | ENA

Rubella virus infection in endothelial cells reduces angiogenesis via interferon betainduced CXCL10

Project description:Rubella virus infection during pregnancy can result in abortion, stillbirth and severe defects in embryogenesis resulting in congenital rubella syndrome (CRS). Low vaccination coverage in developing regions results in estimated 100,000 CRS cases in infants per year with a mortality rate over 30%. The molecular pathomechanisms and potential treatments remain largely unexplored. Endothelial cells (EC) of the placenta are infected by rubella virus (RuV). RuV reduced angiogenic and migratory capacity of primary human EC whereas cell cycle and apoptosis rate were not affected. Next generation sequencing analysis revealed an induction of antiviral type I and III interferons (IFN) that induced angiogenesis-inhibiting cytokines such as CXCL10. The transcriptional profile induced by RuV resembled the effects of IFN-β treatment. The cell culture data were confirmed using human serum from RuV IgM-positive patients that showed similar increase in CXCL10 and inhibited angiogenesis. RuV-mediated inhibition of angiogenesis was reversed by treatment with blocking and neutralizing antibodies targeting CXCL10 and IFN-β receptor. The data identify an important role for anti-viral IFN-mediated induction of CXCL10 in controlling EC function during RuV infection

2023-03-17 | GSE225949 | GEO

Imprinted genes in Capsella rubella

Project description:Genome-wide identification of imprinted genes in C. rubella.

2017-08-23 | GSE76888 | GEO

Rubella Virus wildtype and vaccine strains induce transcription of chemokines and components of innate immunity in human embryonic endothelial cells

Project description:We describe the transcriptional response to infection of human umbilical vein endothelial cells (Huvec) with different rubella virus strains

2022-08-31 | GSE192648 | GEO

Rubella virus

Project description:Rubella virus overview

| PRJNA70673 | ENA

Capsella rubella

Project description:Capsella rubella Genome sequencing

| PRJNA305780 | ENA